Premium
IS THERE ANY ASSOCIATION BETWEEN THE PHARMACOLOGIC CONTROL OF PROLACTIN RELEASE AND ITS ACTION ON MAMMARY CARCINOGENESIS IN THE RAT?
Author(s) -
FEUER G.,
KELLEN J. A.,
KOVACS K.
Publication year - 1977
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1977.tb03339.x
Subject(s) - prolactin , dmba , endocrinology , medicine , carcinogen , phenobarbital , coumarin , chemistry , carcinogenesis , pharmacology , hormone , cancer , biochemistry , organic chemistry
SUMMARY Pretreatment of female Wistar rats with various compounds (coumarin, 4‐methyl‐coumarin, phenobarbital, carbon tetrachloride) on mammary tumour production by 7,12 dimethylbenz(α)anthracene (DMBA) has been studied. The test compounds brought about a variety of actions on DMBA tumours; their effect varied from none (phenobarbital, carbon tetrachloride) to decreased incidence and delayed appearance (coumarin, 4‐methylcoumarin). In all cases studied increased prolactin level was found. The inhibitory action of coumarin on tumour incidence and multiplicity showed a dose‐related association with elevated serum prolactin and reduced hepatic drug metabolism. These results indicate that the production of DMBA‐induced mammary adenocarcinomas in the rat is not associated with serum levels of prolactin. Our results suggest that in this model for tumorigenesis, prolactin only plays the role of a promoter after the carcinogenic event.